Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
Rhea-AI Summary
Scribe Therapeutics (Nasdaq: SCTX) priced its upsized initial public offering of 8,580,000 common shares at $15.00 per share, at the high end of the indicated range, for expected gross proceeds of $128.7 million before expenses. All shares are being sold by Scribe Therapeutics, and the company granted underwriters a 30-day option to buy up to 1,287,000 additional shares at the IPO price, less underwriting discounts and commissions.
The shares are expected to begin trading on the Nasdaq Global Market on July 24, 2026 under the symbol SCTX, with closing anticipated on July 27, 2026, subject to customary conditions. Scribe Therapeutics also agreed to sell 500,000 shares at $15.00 per share in a concurrent private placement to Sanofi, expected to close on the same date, contingent on the IPO closing.
Positive
- IPO gross proceeds expected at $128.7 million from 8,580,000 shares at $15.00
- Upsized IPO priced at high end of the indicated range
- All IPO shares are primary, sold by Scribe Therapeutics for its own account
- Underwriters’ option for up to 1,287,000 additional shares at IPO price
- Concurrent private placement of 500,000 shares to Sanofi at $15.00 per share
Negative
- New share issuance of 8,580,000 IPO shares dilutes existing shareholders
- Additional dilution potential from 1,287,000-share underwriter option and 500,000-share Sanofi placement
News Explained
The priced IPO and agreed Sanofi placement would dilute existing holders if completed; the separate underwriter option is outside the current priced share count.
Scribe Therapeutics has priced its IPO, but the IPO and the agreed Sanofi private placement remain subject to closing conditions and are not completed.
If completed, the two sales would issue new common shares and reduce existing holders’ percentage ownership absent offsetting changes.
The IPO uses an underwritten structure, in which securities are bought by investment banks for resale, while the Sanofi transaction is a private placement to a selected investor outside the public offering.
The separate underwriter option is not included in the current priced IPO share count. The IPO can close without the Sanofi placement, but the placement’s closing depends on the IPO closing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the pricing of its upsized initial public offering of 8,580,000 shares of its common stock at the high end of the range at a public offering price of
Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities and Wells Fargo Securities are acting as joint book-running managers for the offering.
Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on July 23, 2026. The offering is being made only by means of a prospectus. A copy of the final prospectus may be obtained, when available, from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105 or by email at syndicate@leerink.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; and Wells Fargo Securities, LLC, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, by telephone at (800) 645-3751 (option #5) or by email at WFScustomerservice@wellsfargo.com.
In addition to the shares being sold in the initial public offering, Scribe Therapeutics has agreed to sell 500,000 shares of its common stock at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Scribe, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics.
Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com
Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com
